A5052441233- Inflammatory Bowel Disease
- Microscopic Colitis
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Biosimilars and Bioanalytical Methods
- Colorectal Cancer Screening and Detection
- Diverticular Disease and Complications
- Diagnosis and treatment of tuberculosis
- Colorectal Cancer Treatments and Studies
- Liver Diseases and Immunity
- Mycobacterium research and diagnosis
- Pharmacological Effects of Natural Compounds
- Autoimmune and Inflammatory Disorders Research
- SARS-CoV-2 and COVID-19 Research
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal Cancer Surgical Treatments
- Chronic Lymphocytic Leukemia Research
- Intraperitoneal and Appendiceal Malignancies
- Gastrointestinal disorders and treatments
- Gastrointestinal Bleeding Diagnosis and Treatment
- Genetic factors in colorectal cancer
- IgG4-Related and Inflammatory Diseases
- Psoriasis: Treatment and Pathogenesis
- Acute Lymphoblastic Leukemia research
University of Chicago
2016-2025
University of Chicago Medical Center
2024-2025
University of Illinois Chicago
2015
Secukinumab, an interleukin (IL)-17A antagonist, was associated with disease exacerbations in Crohn's disease, and de novo cases of inflammatory bowel (IBD) have been reported studies rheumatoid diseases. However, there has no detailed report demonstrating the linkage between secukinumab therapy new-onset IBD. We present a unique case rapid-onset fulminant colitis after receiving 1 dose infusion followed by improvement combination antibiotics, corticosteroids, calcineurin inhibition. Health...
Abstract Background Ustekinumab has been recently approved for the treatment of moderately to severely active ulcerative colitis (UC). The registry trials ustekinumab in UC demonstrated efficacy and safety, but data on real-world outcomes are limited. We describe effectiveness safety patients with from 2 US tertiary inflammatory bowel disease centers. Methods Patients treated at NYU Langone Health (New York, New York) University Chicago Medical Center (Chicago, Illinois) between January 2016...
Abstract Background Curcumin + Qing Dai (CurQD) is an herbal supplement previously demonstrated in a placebo controlled trial to induce response and remission patients (pts) with active Ulcerative colitis (UC).1 We report the real-world experience from tertiary Inflammatory Bowel Disease center of this nutraceutical pts UC or Crohn’s disease (CD). Methods This retrospective study at University Chicago. included adult IBD who were recommended then received CurQD. CurQD administered as daily...
Abstract Background Bowel wall thickness (BWT) and hyperemia measured by intestinal ultrasound (IUS) predict endoscopic disease activity in Inflammatory Disease (IBD). The clinical significance of mild (mLim1) without BWT is unknown. We previously described the short-term predictive value mLim1 BWT. Here we compare biochemical longer-term outcomes IBD pts with to those normal IUS. Methods reviewed index IUS exams at University Chicago from 7/18/2022 5/7/2024 included (≤3.0mm) + compared them...
Abstract Background A primary objective in the management of Crohn's disease (CD) is prevention bowel tissue damage. The Lémann index (LI) characterizes structural damage based on magnetic resonance enterography (MRE) or computed tomography (CTE) and, for colonic CD, colonoscopy. Intestinal ultrasonography (IUS) provides a non-invasive imaging alternative, though its role LI assessment remains unexplored. This study aimed to establish consensus parameters and standardized acquisition scoring...
Lay Summary We present the clinical cases of 3 brothers, 1 with confirmed diagnosis Crohn’s disease (CD) and 2 inconclusive findings by endoscopy histology demonstrate utility intestinal ultrasound in confirming CD.
ABSTRACT We have demonstrated the effectiveness and safety of combining cyclosporine vedolizumab to treat ulcerative colitis (UC). present 2 cases hospitalized acute severe UC who had failed therapy with antitumor necrosis factor were treated successfully induction safely bridged ustekinumab maintenance therapy. Both patients avoided colectomy. There no adverse events. propose this novel treatment combination in medically resistant UC.
Patients with inflammatory bowel disease (IBD) may receive multiple successive biologic treatments in clinical practice; however, data are limited on the comparative effectiveness of biologics and impact treatment sequence outcomes.
Historically, limits to the ability detect dysplasia in chronic inflammatory bowel disease (IBD)-associated colitis resulted recommendation that neoplasia of any grade be treated by proctocolectomy. We hypothesized with improved optical technologies, most is now detectable and reassessed prevalence colitis-associated neoplasia.We retrospectively reviewed all our patients IBD who had pathologist-confirmed on surveillance colonoscopy underwent a subsequent colectomy. included whose index...
Complete histologic normalization is associated with improved clinical outcomes in ulcerative colitis (UC). However, it currently unknown what effect achieving has on the development of dysplasia.We performed a retrospective analysis 495 patients confirmed diagnosis UC from tertiary center. Patients were categorized according to best assessment they had during their disease course: normalization, quiescence, or persistent activity. We assessed dysplasia rates these patient groups after 8...
Dolinger, Michael Todd MD, MBA1; Krugliak Cleveland, Noa MD2; Rubin, David T. Dubinsky, Marla C. MD1 Author Information